{"filings":[{"id":1332956,"accession_number":"0001193125-26-288390","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-06-29T20:02:39+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet enters $2.75B in new revolving credit facilities, terminates prior agreements","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.5B five-year revolver matures June 2031, with two one-year extension options.","New $1.25B 364-day revolver matures June 2027; both facilities for general corporate purposes.","Prior 2025 credit agreements terminated with no principal outstanding; $0.4M in fees paid.","Borrowings at SOFR plus margin tied to credit rating; leverage covenant max 4.5:1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":698278,"accession_number":"0001193125-26-242207","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-05-27T21:30:16+00:00","items":["5.07","9.01"],"status":"ready","headline":"Zimmer Biomet annual meeting results: all directors elected, shareholder proposal rejected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All ten director nominees elected with strong support; votes ranged from 160.9M to 167.5M for.","Ratification of PwC as auditor for 2026 passed: 172.7M for, 7.9M against.","Advisory approval of named executive officer compensation passed: 160.1M for, 8.4M against.","Shareholder proposal for independent board chairman rejected: 31.3M for, 137.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22005,"accession_number":"0001193125-26-218098","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-05-12T10:30:17+00:00","items":["7.01","5.02","9.01"],"status":"ready","headline":"Zimmer Biomet increases FY2026 share repurchase target to $1B, up $250M from prior view","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Now expects to repurchase up to $1.0B of common stock in FY2026, a $250M increase from prior assumption.","Repurchases will be made under existing $1.5B authorization approved by Board in February 2026.","No changes to size, duration or terms of the authorization.","May conduct open-market purchases or structured agreements; timing depends on market conditions, stock price, and capital availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91503,"accession_number":"0001193125-26-183430","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zimmer Biomet CFO Suketu Upadhyay resigns; Paul Stellato named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Suketu Upadhyay resigns as CFO and EVP effective April 28, 2026, to pursue a new opportunity.","Paul Stellato, currently Controller and CAO, appointed interim CFO effective April 28.","Stellato receives $550K annual base salary (prorated), 70% target bonus, and $850K in equity grants.","Company has begun internal and external search for a permanent CFO.","Departure not due to any disagreement on financial statements or controls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91502,"accession_number":"0001193125-26-183411","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ZBH Q1 net sales $2.09B (+9.3% reported); adj EPS $2.09 (+15.5%); raises FY adj EPS guidance to $8.40-$8.55","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $2.087B, +9.3% reported, +6.8% constant currency, +2.9% organic constant currency.","GAAP diluted EPS $1.22 (+34.1%); adjusted diluted EPS $2.09 (+15.5%).","Operating cash flow $359.4M, free cash flow $245.9M in Q1.","Repurchased $250M of shares during the first quarter.","FY2026 adj EPS guidance raised to $8.40-$8.55 (from $8.30-$8.45); organic CC revenue guidance unchanged at 1-3%."],"consensus_eps_estimate":1.883,"consensus_eps_actual":1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":2086700000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101623,"accession_number":"0001193125-26-043620","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q4 and FY2025 results; specifics not available in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued February 10, 2026, for quarter and year ended December 31, 2025.","Exhibit 99.1 containing financial results was not appended to this filing.","No specific revenue, EPS, or guidance figures are provided in the body of the 8-K.","Investors should refer to the separate press release for detailed financial data."],"consensus_eps_estimate":2.4199,"consensus_eps_actual":3.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":8231500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101622,"accession_number":"0001193125-26-009895","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zimmer Biomet NEO Mark Bezjak resigning employment effective Jan 16, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Bezjak, a named executive officer in the 2025 proxy statement, resigned all officer positions effective January 16, 2026.","Bezjak had previously ceased being an executive officer on July 1, 2025.","Departure is to pursue another business opportunity; no successor announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117968,"accession_number":"0001193125-25-265649","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q3 2025 results; press release attached but not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing furnishes press release under Item 2.02 for quarter ended September 30, 2025.","Exhibit 99.1 (press release) is referenced but its content is not included in the input text.","No specific financial figures or guidance changes can be extracted from the available filing."],"consensus_eps_estimate":1.8862,"consensus_eps_actual":2.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":5987700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117967,"accession_number":"0001193125-25-233473","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zimmer Biomet completes acquisition of Monogram Technologies for $4.04/sh plus CVRs up to $12.37","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each Monogram common share converted to $4.04 cash and non-tradeable CVRs worth up to $12.37 upon milestone achievement.","Acquisition adds AI-driven semi- and fully autonomous robotics for TKA; FDA 510(k) clearance March 2025, commercialization expected early 2027.","Zimmer Biomet now offers broadest orthopedic robotics portfolio including ROSA platform; nearing 2,000 installations worldwide.","Monogram shares ceased trading on NASDAQ and will be delisted as of October 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134427,"accession_number":"0001193125-25-196060","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zimmer Biomet issues CHF 600M in two tranches of senior unsecured bonds due 2030 and 2035","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CHF 210M 0.930% bonds due Sept 4, 2030 (Tranche A) and CHF 390M 1.560% bonds due Sept 4, 2035 (Tranche B) issued.","Interest payable annually in arrears starting Sept 4, 2026; bonds are senior unsecured.","Redemption provisions include 3-months par call and clean-up call; holders can require repurchase upon a Change of Control Triggering Event.","Issued under bond purchase and paying agency agreement dated Sept 2, 2025 with joint lead managers.","Proceeds not stated; bonds denominated in Swiss francs and governed by the BPPAA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134426,"accession_number":"0000950170-25-104527","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q2 2025 earnings released; specific figures not in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for quarter ended June 30, 2025 issued on August 7, 2025.","Exhibit 99.1 containing financial results is not appended in the provided text.","No revenue, EPS, or other performance data available from the 8-K body.","Investors should refer to the separate press release for detailed results."],"consensus_eps_estimate":2.0035,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":3986400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134425,"accession_number":"0001193125-25-158442","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zimmer Biomet to acquire Monogram Technologies for ~$177M upfront plus CVR up to $12.37/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Equity value ~$177M ($4.04/share cash upfront); enterprise value ~$168M.","Common stockholders receive non-tradeable CVR up to $12.37/share if product, regulatory and revenue milestones through 2030 are met.","Acquisition neutral to adjusted EPS in 2025-2027, accretive in 2028+; expected to contribute to revenue growth beginning 2027.","Monogram's semi-autonomous TKA robot (FDA 510(k) March 2025) and fully autonomous system in development will expand Zimmer Biomet's ROSA robotics platform.","Closing expected later this year, subject to Monogram stockholder approval, regulatory clearances and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151250,"accession_number":"0001193125-25-152694","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet enters $1.5B five-year and $1.0B 364-day revolving credit facilities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $1.5B five-year unsecured revolver maturing June 27, 2030, with two one-year extension options.","Also entered $1.0B 364-day unsecured revolver maturing June 26, 2026.","Borrowed $50M under the five-year facility to replace portion of prior borrowings; terminated 2024 credit agreements.","Prior 2024 agreements had ~$50.7M outstanding; $50M refinanced, $0.7M repaid from cash.","Facilities include incremental feature up to $500M and letter of credit sublimit of $50M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151249,"accession_number":"0000950170-25-080567","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"ZBH shareholders approve 10M share increase to stock plan and officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2009 Stock Incentive Plan: 10M share increase, term to 2035, independent contractors eligible.","Shareholders approved officer exculpation amendment to charter, limiting liability for breach of duty of care.","Votes: Plan 154.4M for (89.7% of votes cast); exculpation 149.2M for (88.7%); all directors elected with >96% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151248,"accession_number":"0001193125-25-126231","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zimmer Biomet appoints Kevin Thornal as Group President, Global Businesses and the Americas effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thornal appointed to new role effective July 1; reports to CEO Ivan Tornos, leads Americas and global business units.","Former Nevro CEO and Hologic Group President; previously held leadership at Stryker.","Mark Bezjak remains President Americas but ceases as executive officer upon Thornal's start.","Compensation: $850k base, 100% target bonus, ~$5.3M in equity (RSUs + PRSUs); eligible for severance plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151247,"accession_number":"0000950170-25-063124","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q1 rev +1.1%; guides 2025 adj EPS down to $7.90-$8.10, rev up including Paragon 28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $1.909B (+1.1% reported, +2.3% CC); GAAP EPS $0.91, adjusted EPS $1.81.","2025 adjusted EPS guidance lowered to $7.90-$8.10 from $8.15-$8.35 due to Paragon 28, currency, and tariffs.","2025 reported revenue guidance raised to 5.7%-8.2% (includes Paragon 28); organic CC unchanged at 3%-5%.","Completed acquisition of Paragon 28 (foot and ankle orthopedics) in Q1 2025.","Chairman Begley retiring at May 29 meeting; CEO Tornos to become Chairman, Farrell Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1909100000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151246,"accession_number":"0001193125-25-087219","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zimmer Biomet completes acquisition of Paragon 28 for $13.00/share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closing on April 21, 2025; each Paragon 28 share converted to $13.00 cash plus up to $1.00 CVR tied to revenue milestones.","Paragon 28 becomes wholly-owned subsidiary; delisted from NYSE effective April 21, 2025.","Deal strengthens Zimmer Biomet's foot and ankle segment, a ~$5B market growing high-single digits.","Leverages Paragon 28's dedicated sales channel to accelerate ASC penetration and global growth.","Transaction expected to accelerate Zimmer Biomet's weighted-average market growth rate (WAMGR)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170143,"accession_number":"0001193125-25-035147","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zimmer Biomet announces Chairman Christopher Begley to retire; CEO Ivan Tornos to succeed as Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Begley will retire from board at May 29, 2025 annual meeting due to mandatory retirement policy.","President and CEO Ivan Tornos appointed Chairman of the Board effective May 29, 2025.","Michael Farrell named Lead Independent Director, effective upon Tornos becoming Chairman.","Board size reduced to ten members after Begley's term expires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170142,"accession_number":"0001193125-25-029614","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet issues $1.75B in three tranches of notes; special redemption tied to Paragon 28 merger","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M 4.700% notes due 2027, $550M 5.050% notes due 2030, and $600M 5.500% notes due 2035.","Interest payable semi-annually on Feb 19 and Aug 19, commencing Aug 19, 2025.","If Paragon 28 merger not closed by Nov 28, 2025 (extendable to Jan 28, 2026) or agreement terminated, 2030/2035 notes redeemable at 101% plus accrued interest.","2027 notes not subject to special mandatory redemption and will remain outstanding even if merger fails.","Change of control repurchase offer at 101% of principal plus accrued interest for each series."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170141,"accession_number":"0001193125-25-028618","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zimmer Biomet issues $1.75B in notes at 4.700%, 5.050%, and 5.500%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering includes $600M 4.700% notes due 2027, $550M 5.050% notes due 2030, and $600M 5.500% notes due 2035.","Interest payable semi-annually; closing expected February 19, 2025 subject to customary conditions.","Net proceeds to redeem a portion of the outstanding 3.550% notes due 2025 and for general corporate purposes.","Underwriters include Goldman Sachs, Barclays, Citi, Morgan Stanley, and SMBC Nikko."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170140,"accession_number":"0000950170-25-014972","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.","Full-year net sales $7.679B (+4.8% CC); full-year adjusted diluted EPS $8.00.","FY2025 guidance: constant currency revenue growth 3%-5%; adjusted diluted EPS $8.15-$8.35.","Announced definitive agreement to acquire Paragon 28 (FNA) for foot & ankle segment; terms not disclosed.","Received FDA PMA for Oxford Cementless Partial Knee and FDA 510(k) for OsseoFit Stemless Shoulder."],"consensus_eps_estimate":null,"consensus_eps_actual":4.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":7678600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170139,"accession_number":"0001193125-25-014881","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zimmer Biomet to acquire Paragon 28 for $13.00 per share cash plus up to $1.00 CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal consideration: $13.00 per share cash plus Contingent Value Right (CVR) with max $1.00 payable if Paragon 28 net revenue exceeds $361M in 2026.","Paragon 28 CEO Albert DaCosta enters voting agreement to support deal, will become Global President, Foot and Ankle post-close.","Termination fee of $40M payable by Paragon 28 under certain circumstances, including if it accepts a superior proposal.","Closing requires stockholder approval, HSR and foreign regulatory clearances; no financing condition.","Deal expected to close by November 28, 2025 (with possible extension to January 28, 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170138,"accession_number":"0001193125-25-014569","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zimmer Biomet to acquire Paragon 28 for $1.2B enterprise value, $13/share cash plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $13.00 per share cash (~$1.1B equity); CVR up to $1.00/share if FY2026 net sales exceed $346M.","Paragon 28 FY2024 revenue $255.9–$256.2M (+18.2–18.4% YoY); targets ~$5B foot & ankle segment growing high-single digits.","Deal ~3% dilutive to ZBH adj. EPS in 2025, ~1% dilutive in 2026, accretive within 24 months; close H1 2025 subject to approvals.","Unanimous board approval; Goldman Sachs advising ZBH, Piper Sandler advising Paragon 28."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187154,"accession_number":"0001193125-24-262540","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet issues €700M of 3.518% notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€700M aggregate principal, 3.518% annual interest, matures Dec 15, 2032.","Interest payable annually on December 15, starting December 15, 2025.","Before Sept 15, 2032, redeemable at greater of present value plus 20bps or par, plus accrued interest.","On or after Sept 15, 2032, redeemable at 100% of principal plus accrued interest.","Change of control triggers repurchase at 101% of principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187153,"accession_number":"0001193125-24-261733","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zimmer Biomet prices €700M 3.518% notes due 2032; proceeds to repay 2024 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €700M aggregate principal of 3.518% notes due December 15, 2032.","Interest payable annually; first payment December 15, 2025.","Offering scheduled to close November 20, 2024; underwriters led by Barclays, Goldman Sachs, HSBC, RBC.","Net proceeds to be used to repay a portion of $850M 1.450% notes maturing 2024.","Notes issued under eleventh supplemental indenture to base indenture dated 2009."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187152,"accession_number":"0000950170-24-118573","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.","FY2024 constant currency revenue growth guidance narrowed to 4.25%-4.75% from 5.0%-6.0%.","FY2024 adjusted diluted EPS guidance lowered to $7.95-$8.05 from $8.00-$8.15.","CEO Ivan Tornos cited ERP implementation challenges as headwind to full-year performance.","Completed acquisition of OrthoGrid Systems (AI hip guidance); launched Z1 Femoral Hip System."],"consensus_eps_estimate":null,"consensus_eps_actual":3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":5655400000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203666,"accession_number":"0001193125-24-201328","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet issues $700M of 5.200% notes due 2034","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $700M aggregate principal of 5.200% notes maturing Sep 15, 2034.","Interest at 5.200% payable semi-annually on Mar 15 and Sep 15, beginning Mar 15, 2025.","Notes redeemable at par after Jun 15, 2034; prior to that at Treasury rate plus 20 bps.","Upon Change of Control Repurchase Event, holders can require repurchase at 101% of principal plus accrued interest.","Issued under shelf registration; trustee is Computershare Trust Company, N.A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203665,"accession_number":"0001193125-24-200634","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zimmer Biomet prices $700M of 5.200% senior notes due 2034","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $700M aggregate principal amount of 5.200% notes due 2034; closing August 15, 2024.","Interest payable semi-annually on March 15 and September 15, commencing March 15, 2025.","Notes mature September 15, 2034; net proceeds to repay 1.450% notes due 2024 and credit facilities.","Underwriting agreement with Barclays, BNP Paribas, BofA Securities, Citigroup, and J.P. Morgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203664,"accession_number":"0000950170-24-092996","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"No material event identified; filing contains only XBRL metadata","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing text consists solely of XBRL taxonomy elements and dates, not narrative disclosure.","No press release, financial results, or other substantive information provided.","Unable to extract any specific investor-relevant event from the submitted content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203663,"accession_number":"0000950170-24-092253","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.","Net earnings $242.8M GAAP; adjusted net earnings $415.0M.","FY 2024 reported revenue guidance lowered to 4.0%-5.0% on FX; CC revenue growth 5.0%-6.0% and adjusted EPS $8.00-$8.15 reaffirmed.","Signed definitive agreement to acquire OrthoGrid Systems (AI hip guidance); also entered THINK Surgical and CBRE partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":3831200000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203662,"accession_number":"0001193125-24-173303","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet enters new $1.5B five-year and $1.0B 364-day credit facilities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.5B unsecured five-year revolving credit facility maturing June 28, 2029.","New $1.0B unsecured 364-day revolving credit facility maturing June 27, 2025.","Prior 2023 credit agreements terminated; no borrowings outstanding at termination.","Borrowings bear floating SOFR-based interest plus margin tied to credit rating.","Five-year facility includes $500M uncommitted incremental feature and two one-year extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220195,"accession_number":"0000950170-24-075310","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zimmer Biomet appoints Embecta CEO Devdatt Kurdikar to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11 members; Devdatt Kurdikar appointed effective June 20, 2024.","Kurdikar serves as President & CEO of Embecta Corp. (Nasdaq: EMBC), a diabetes management spinoff from BD.","He will serve on the Corporate Governance Committee and Compensation & Management Development Committee.","His term expires at the 2025 annual meeting; standard non-employee director compensation applies.","No arrangements or material interests disclosed; indemnification agreement expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220194,"accession_number":"0000950170-24-060580","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ZBH shareholders approve 10M-share increase to Employee Stock Purchase Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All ten director nominees elected; PwC ratified as independent auditor for 2024.","Advisory say-on-pay proposal received ~90.4% support from votes cast.","ESPP amendments also include administrative and best-practice changes.","ESPP share reserve increased by 10,000,000 shares for future purchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220193,"accession_number":"0000950170-24-051551","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q1 net sales $1.889B (+3.2%); adj. EPS $1.94; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.889B, up 3.2% reported and 4.4% constant currency; GAAP diluted EPS $0.84, adjusted $1.94.","Knees $788.1M (+3.4%), Hips $491.2M (-0.3%), S.E.T. $452.6M (+4.4%).","Reiterates FY2024 guidance: constant currency revenue growth 5-6%, adjusted EBITDA $8.00-$8.15 EPS.","FDA 510(k) clearance for ROSA Shoulder System (first robotic shoulder assist) and Z1 Femoral Hip Stem."],"consensus_eps_estimate":null,"consensus_eps_actual":0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":1889200000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239884,"accession_number":"0000950170-24-012530","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q4 2023 net sales $1.94B (+6.3%), adj EPS $2.20; guides FY24 adj EPS $8.00-$8.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.94B (+6.3% reported, +6.1% CC); diluted EPS $2.01, adjusted $2.20.","Full-year 2023 net sales $7.39B (+6.5% reported, +7.5% CC); adjusted EPS $7.55.","FY 2024 guidance: constant currency revenue growth 5.0%-6.0%; adjusted diluted EPS $8.00-$8.15.","FDA closed out Warning Letter for Warsaw North Campus; global restructuring targeting ~$200M run-rate savings by 2025.","Completed $500M share buyback in Jan 2024; appointed Louis Shapiro to board."],"consensus_eps_estimate":null,"consensus_eps_actual":4.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":7394200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239883,"accession_number":"0001193125-24-002878","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Appoints Louis A. Shapiro, former HSS CEO, to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from ten to eleven members; Shapiro fills new vacancy.","Louis A. Shapiro was President/CEO of Hospital for Special Surgery (HSS), retiring Oct 2023.","Shapiro appointed to Audit Committee and Quality, Regulatory and Technology Committee.","Shapiro brings industry leadership and customer perspective; no arrangements with any person for appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257411,"accession_number":"0001193125-23-287490","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet issues $500M of 5.350% Notes due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M aggregate principal of 5.350% Notes due December 1, 2028; interest payable semi-annually.","Notes redeemable prior to Nov 1, 2028 at Treasury Rate plus 20 bps plus accrued interest.","Change of control triggers repurchase at 101% of principal plus accrued interest.","Underwriting agreement with Barclays, Goldman Sachs, Mizuho, Morgan Stanley as underwriters.","Notes issued under Ninth Supplemental Indenture with Computershare Trust as trustee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257410,"accession_number":"0000950170-23-059736","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q3 2023 results; press release details not provided in filing extract","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued November 7, 2023 covering quarter ended September 30, 2023.","No revenue, EPS, or other financial figures available from the 8-K excerpt provided.","Investors should refer to the full press release for specific earnings data."],"consensus_eps_estimate":null,"consensus_eps_actual":2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":5454100000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274749,"accession_number":"0001193125-23-217504","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zimmer Biomet appoints Ivan Tornos as CEO, Christopher Begley as Chairman; Suketu Upadhyay expands role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan Hanson steps down as Chairman, President & CEO effective Aug 22, 2023; remains advisory through Aug 31.","Ivan Tornos, former COO, appointed President & CEO; elected to Board.","Christopher Begley appointed Chairman of the Board (from Lead Independent Director).","Suketu Upadhyay expands role to CFO & EVP, Finance, Operations & Supply Chain.","Company reaffirms full-year 2023 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274748,"accession_number":"0000950170-23-036153","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q2 2023 earnings on Aug 1, 2023; details in attached press release","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for quarter ended June 30, 2023 was issued on August 1, 2023.","No specific financial figures are included in the filing body; the actual data is in Exhibit 99.1, which was not provided in this excerpt.","Results are furnished under Item 2.02 and not considered filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3700600000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274747,"accession_number":"0001193125-23-184743","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet enters $1.5B five-year and $1B 364-day credit facilities, refinances $520M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.5B five-year unsecured revolving facility matures July 7, 2028, with two one-year extension options.","New $1.0B 364-day unsecured revolving facility matures July 5, 2024.","Borrowed $520M under the five-year facility to repay outstanding borrowings under prior five-year credit agreement.","Financial covenant requires consolidated indebtedness to EBITDA ratio ≤4.5x (5.0x for material acquisitions).","Interest rates based on adjusted Term SOFR plus margin determined by credit rating; facility fees also based on credit rating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292064,"accession_number":"0001193125-23-169043","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Zimmer Biomet files resale registration for common stock via prospectus supplement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filing is solely for opinion of counsel regarding legality of shares being registered for resale by selling stockholders.","No new financial or operational information disclosed; routine registration matter.","Prospectus supplement filed on June 16, 2023; shares may be sold by selling stockholders from time to time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292063,"accession_number":"0001193125-23-146173","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zimmer Biomet shareholders elect 10 directors, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with at least 161M votes For each.","Auditor ratification (PwC) passed: 179.6M For, 6.1M Against.","Say-on-pay advisory proposal approved: 154.3M For, 16.6M Against.","Advisory vote on frequency set to one year (168.6M votes for one year).","Board adopts annual say-on-pay frequency until next advisory vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292062,"accession_number":"0000950170-23-016423","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.","U.S. knee sales $448.2M (+18.1% YoY); hip sales $252.3M (+12.3% YoY).","Raises FY2023 adjusted EPS guidance to $7.40-$7.50 (prior $6.95-$7.15); reported revenue growth 5.0-6.0% (prior 1.5-3.5%).","Completed acquisition of Embody, Inc., adding collagen-based biointegrative solutions to sports medicine.","Launched Persona OsseoTi Keel Tibia for cementless knee replacement; ZBEdge platform enhancements at AAOS 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1831000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312812,"accession_number":"0001193125-23-040223","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Zimmer Biomet files legal opinion for resale registration of common stock","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Shares registered for resale by certain selling stockholders; no new issuance or operational change.","Legal opinion from Faegre Drinker Biddle & Reath LLP on legality of shares.","No financial results, guidance, or other material events reported in this filing.","This filing is procedural and does not affect company's business or capital structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312811,"accession_number":"0000950170-23-001740","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q4 and FY2022 results; no figure details in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release on February 3, 2023 covering Q4 and full-year 2022 financial performance.","Actual financial results not provided in the 8-K text; refer to attached Exhibit 99.1.","Investors should review the press release for specific revenue, EPS, and segment data.","No forward-looking guidance or material events disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":6939900000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331320,"accession_number":"0001193125-22-304888","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zimmer Biomet amends bylaws to implement Rule 14a-19 procedural requirements for director nominations","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders must certify compliance with Rule 14a-19 and provide reasonable evidence no later than five business days before meeting.","If stockholder fails to comply or withdraws, nominations deemed null and void; proxies for such nominees disregarded.","White proxy cards reserved exclusively for use by Board of Directors.","Bylaws also incorporate other technical, clarifying, and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331319,"accession_number":"0000950170-22-020960","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q3 2022 results; details in press release not provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on Nov 2, 2022, reporting Q3 2022 financial results via press release.","Press release attached as Exhibit 99.1 but not included in the provided text.","No specific financial figures available for summary.","Investors should refer to the full press release for detailed results."],"consensus_eps_estimate":null,"consensus_eps_actual":1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":5114800000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348875,"accession_number":"0001193125-22-226467","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2022-08-22T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zimmer Biomet enters $1.5B five-year and $1.0B 364-day revolving credit facilities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.5B five-year unsecured revolving credit facility matures August 19, 2027, with two one-year extension options.","New $1.0B 364-day unsecured revolving credit facility matures August 18, 2023; both for general corporate purposes.","Prior 2021 five-year and 364-day credit agreements terminated; no borrowings were outstanding at termination.","Five-year facility has an uncommitted incremental feature allowing up to $500M additional capacity.","Interest based on adjusted Term SOFR plus margin determined by credit rating; leverage covenant max 4.5x EBITDA (5.0x for material acquisitions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348874,"accession_number":"0000950170-22-013732","cik":1136869,"company_name":"ZIMMER BIOMET HOLDINGS, INC.","ticker":"ZBH","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zimmer Biomet reports Q2 2022 results via press release; details not available in provided filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release (Exhibit 99.1) referenced but not appended; specific financial figures cannot be extracted.","Filing indicates results for quarter ended June 30, 2022 were issued on August 2, 2022.","No revenue, EPS, or segment data available in the provided 8-K text."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3445000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16653250000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-02T23:59:59+00:00|348874"}